New updates have been reported about Verismo Therapeutics.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Verismo Therapeutics has obtained a $28 million capital infusion from parent company HLB Innovation to accelerate clinical development of its proprietary KIR-CAR T cell platform in solid and hematologic tumors. The funding is timed to support ongoing Phase 1 studies of SynKIR-110 in advanced mesothelin-positive solid tumors and SynKIR-310 in relapsed or refractory B cell non-Hodgkin lymphoma, with both assets positioned as next-generation alternatives to conventional CD3-based CAR T therapies.
A major near-term catalyst for Verismo will be the first public disclosure of KIR-CAR clinical data at the AACR 2026 Annual Meeting, where initial results from the STAR-101 trial of SynKIR-110 will be showcased in a Late-Breaking Clinical Trials plenary session. Additional AACR presentations will highlight preclinical performance of SynKIR-310 versus standard second-generation CAR Ts in lymphoma models and data showing EGFR-targeted KIR-CAR T cells overcoming resistance in glioblastoma, underscoring the platform’s potential to address high unmet-need indications and support future partnering or financing.
Chief Executive Officer Bryan Kim stated that the new investment provides sufficient financial runway to drive both solid tumor and blood cancer programs toward critical data inflection points that will clarify the commercial and clinical viability of multi-chain KIR-CAR technology. Verismo’s approach uses an NK cell–derived KIR receptor paired with DAP12 to decouple target recognition from T cell activation, aiming to reduce T cell exhaustion, sustain receptor expression, and improve durability of response relative to single-chain CAR T constructs.
As the only company currently developing a KIR-CAR platform, Verismo is seeking to differentiate itself in an increasingly crowded cell therapy landscape by demonstrating efficacy in indications where standard CAR T has struggled, particularly solid tumors. The Phase 1 data package emerging from STAR-101 and CELESTIAL-301, combined with the high-profile AACR selection, may shape Verismo’s strategic options around future capital raising, partnering, and potential expansion of its pipeline into additional solid and B cell–driven diseases.
The company’s technology is supported by intellectual property licensed from the University of Pennsylvania, whose Perelman School of Medicine receives research funding tied to Verismo’s programs and could obtain future financial benefits from successful development. While the outcomes of ongoing trials remain subject to clinical, regulatory, and market risks, the new investment materially strengthens Verismo’s ability to execute on its current studies and positions the company for a series of value-defining data readouts beginning in April 2026.